Clinical Significance of SEC11A Expression in Patients With Locally Advanced Gastric Cancer.
By: Hideaki Suematsu, Kentaro Sakamaki, Naohide Oue, Yukihiko Hiroshima, Yayoi Kimura, Shizune Onuma, Itaru Hashimoto, Shinsuke Nagasawa, Toru Aoyama, Takanobu Yamada, Hiroshi Tamagawa, Takashi Ogata, Yasushi Rino, Munetaka Masuda, Wataru Yasui, Yohei Miyagi, Takashi Oshima

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
2022-10-2; doi: 10.21873/anticanres.16097
Abstract

Background/aim

SEC11A gene encodes the SPC18 protein, which has been implicated in tumour progression by inducing the secretion of various growth factors. We investigated the clinical significance of SEC11A expression in gastric cancer (GC) tissues in patients with locally advanced gastric cancer (LAGC) after curative resection.

Patients

We estimated SEC11A expression in cancer tissues from 253 pStage II/III GC patients who underwent curative resection using quantitative polymerase chain reaction (PCR) and investigated the relationship of SEC11A expression with clinicopathological factors and survival.

Results

SEC11A expression was significantly related to serosal invasion, lymph node metastasis, lymphatic invasion, and pathological stage. The high-SEC11A expression group had a significantly lower survival rate than the low group (5-year survival 52.3% vs. 75.9%; p<0.005). Furthermore, in multivariate analysis, high-SEC11A expression was an independent factor of poor survival (hazard ratio, 2.010; 95% confidence interval=1.303-3.100; p=0.002).

Conclusion

SEC11A expression in cancer tissue may be a useful prognostic marker in patients with LAGC after curative resection.



Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PMID:36456166






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements